Assay

Financial-condition grades for SEC filers

Company Report · as of Oct 9, 2026


HomeCompaniesSectorsCalendarLast night

Immuneering Corp.IMRX · healthcare
GradeNonecomputable_factors_below_threshold: 4 of 14 inputs computable; 7 are required
Reliability0.87 AUCfailure model, filers with $120M to $591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025
Peer failure rate1.03% a yearItem 1.03 bankruptcies, same asset band, 2012 to 2025
Size band$120M to $591M assetstotal assets $232.0M[1]
Standard universeoutsiderevenue above $1M and assets above $10M[1-2]
Warningsthin data, degenerate inputsnot computable: dilution, distress, fortress balance sheet
Inputs computable4 of 14
Graded fromfilings received through Mar 6, 2026217 days before the rescan; every figure keyed to the SEC receipt date
Last close$3.722026-10-08; market equity $96.5M; iex feed
Price used in gradeNone
Share price, twelve months to the rescansplit-adjusted close; a lollipop at every rescan carries the letter held then; baseline ticks are SEC receipt dates of the inputs; ranges and dragging scroll the full history
$4$6$8NovDecJanFebMarAprMayJunJulAugSepOct$3.74
ABCDE20132014201520162017201820192020202120222023202420252026

Percentile at every rescan on file, Jan 21, 2012 to Oct 9, 2026; stronger toward the top. Hover for the date.

Open this report as it stood on

Letter setLetterPercentileBand
Jan 21, 2012nonen/a
Mar 21, 2022nonen/aQ3
Mar 21, 2024nonen/aQ2
Mar 21, 2026nonen/aQ3

Each date opens the report as it stood on that rescan.

Business, in the company's words. Opening of Item 1 of the 10-K received Mar 6, 2026; the document on sec.gov.

We are a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive. We are developing and seeking to commercialize an entirely new category of anti-cancer medicines, Deep Cyclic Inhibitors, which we believe have the potential to be more effective and better tolerated targeted therapies. Deep Cyclic Inhibition® ("DCI") is a novel mechanism that aims to deprive tumor cells of the sustained proliferative signaling required for rapid growth, while sparing healthy cells through a cadenced, normalized level of signaling.

Warnings [top]

Thin data. 4 of 14 grade factors are computable; minimum is 7
Degenerate inputs. latest revenue or assets are at or below the $100,000 validity floor[1-2]

7 checks ran; none of them enters the letter. The checks are listed on the warnings screen.

The Fourteen Inputs [top]

Lower percentile is stronger. Source numbers open the SEC filing; a range that spans filings opens the sources table.

InputPercentile, 0 to 100ValueSourcePeer medianPercentilePeersPeriod end
Profitability, sleeve percentile 52.1
Gross profitabilitynot computable32.2%
latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31
Return on invested capitalnot computable9.3%
one or more required annual facts are missing
Accruals ratio(7.5%)[1,3-5](6.6%)52.18112025-12-31
Gross margin stability, five yearsnot computable2.8 pts
five annual gross margins are required; found 3
Solvency, sleeve percentile 4.5
Twelve-month failure probabilitynot computable0.07%
liabilities and a nearby cover-page share count are required at 2026-06-30
Altman Z double-prime16.03[1,6-11](0.31)3.87562025-12-31
Net debt to EBITDAnot computable1.82x
one or more required annual facts are missing
Interest coveragenot computable(4.51x)
one or more required annual facts are missing
Current ratio17.50x[6-7]2.96x5.18392025-12-31
Growth and financing, sleeve percentile 18.2
Revenue growth, three-year compoundnot computable10.0%
four annual observations are required; found 3
Free cash flow growth, three-year compoundnot computable10.9%
current FCF must be positive and base FCF must exceed $100,000
Reinvestment ratenot computable37.1%
a prior annual working-capital observation is required
Asset growth, three years23.8%[1,5,12-13]2.1%18.27042025-12-31
Net share issuance, one yearnot computable2.5%
two annual share counts are required; found 0

Gross profitability. Revenue less cost of goods sold, over total assets.

Accruals ratio. Net income less operating cash flow, over average assets; lower is stronger.

Gross margin stability, five years. Standard deviation of gross margin; lower is stronger.

Twelve-month failure probability. CHS model; lower is stronger.

Net debt to EBITDA. Lower is stronger.

Net share issuance, one year. Split-adjusted; lower is stronger.

Among 371 Peers [top]

What the Price Implies [top]

Market measures at the 2026-10-08 close. None enters the grade. Percentile among graded peers with the same measure.

MeasureValuePeer medianPercentileReading
Twelve-month price change, skipping the latest month(28.7%)8.0%26hotter than 26 of 100 peers
Distance from 52-week high(55.1%)(31.4%)21closer to its high than 21 of 100 peers
EBIT to enterprise valuenot computable(1.5%)required accounting or market input is missing
Free cash flow yield(46.9%)(1.0%)13pricier than 87 of 100 peers
Book value to price1.970.2896pricier than 4 of 100 peers
Sales to price0.000.310pricier than 100 of 100 peers
Composite equity issuance, five yearsnot computable20.3%required accounting or market input is missing
Relative strength against the sector, log excess return(0.55)(0.14)26ahead of 26 of 100 peers

Inputs: market equity $97.0M; EBIT -$59.4M; free cash flow -$45.5M; book equity $190.7M; sales $0; cash $41.3M[14].

Diagnostics [top]

Diagnostics do not feed the grade.

Piotroski F-score: None of 9, period end 2025-12-31
Return on assets above zero(106.3%)✗ fail[3,5]
Operating cash flow above zero-$45.3M✗ fail[4]
Return on assets improved(46.8 pts)✗ fail[3,5,12,15]
Operating cash flow exceeds net income$10.7M✓ pass[3-4]
Long-term leverage felln/a[1,5,12]
Current ratio improved1,222.0 pts✓ pass[6-7,16-17]
No new shares issuedn/a
Gross margin improvedn/a
Asset turnover improvedn/a[5,12]
Cash, filings, liquidity
Cash and equivalents$41.3M[18]
Operating cash flow, four quarters-$56.8M[4,18-22]
Months of runway8.7
Late filings, two years0
NT 10-K or NT 10-Q
Days since last periodic filing65
10-Q received Aug 5, 2026
Median daily dollar volume$2.8M
63 sessions
Days since newest grade input217

Downloads [top]

Sources [top]

Every citation on this page. Filing opens the SEC index page for that submission; viewer opens the SEC interactive data for the same filing; series opens the SEC XBRL API record for that tag and company.

#ConceptXBRL tagValuePeriod endReceivedFormLinks
1assetsus-gaap:Assets$232.0M2025-12-312026-03-0610-Kfiling · viewer · series
2revenueus-gaap:Revenues$02023-12-312024-03-0110-Kfiling · viewer · series
3net incomeus-gaap:NetIncomeLoss-$56.0M2025-12-312026-03-0610-Kfiling · viewer · series
4operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$45.3M2025-12-312026-03-0610-Kfiling · viewer · series
5assetsus-gaap:Assets$52.7M2024-12-312026-03-0610-Kfiling · viewer · series
6current assetsus-gaap:AssetsCurrent$176.2M2025-12-312026-03-0610-Kfiling · viewer · series
7current liabilitiesus-gaap:LiabilitiesCurrent$10.1M2025-12-312026-03-0610-Kfiling · viewer · series
8retained earningsus-gaap:RetainedEarningsAccumulatedDeficit-$280.3M2025-12-312026-03-0610-Kfiling · viewer · series
9operating incomeus-gaap:OperatingIncomeLoss-$59.4M2025-12-312026-03-0610-Kfiling · viewer · series
10book equityus-gaap:StockholdersEquity$218.5M2025-12-312026-03-0610-Kfiling · viewer · series
11liabilitiesus-gaap:Liabilities$13.5M2025-12-312026-03-0610-Kfiling · viewer · series
12assetsus-gaap:Assets$102.6M2023-12-312025-03-2010-Kfiling · viewer · series
13assetsus-gaap:Assets$122.4M2022-12-312024-03-0110-Kfiling · viewer · series
14shares outstandingdei:EntityCommonStockSharesOutstanding25,938,0642021-09-032021-09-0910-Qfiling · viewer · series
15net incomeus-gaap:NetIncomeLoss-$61.0M2024-12-312026-03-0610-Kfiling · viewer · series
16current assetsus-gaap:AssetsCurrent$39.6M2024-12-312026-03-0610-Kfiling · viewer · series
17current liabilitiesus-gaap:LiabilitiesCurrent$7.5M2024-12-312026-03-0610-Kfiling · viewer · series
18cashus-gaap:CashAndCashEquivalentsAtCarryingValue$41.3M2026-06-302026-08-0510-Qfiling · viewer · series
19operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$34.9M2026-06-302026-08-0510-Qfiling · viewer · series
20operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$18.4M2026-03-312026-05-1510-Qfiling · viewer · series
21operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$35.5M2025-09-302025-11-1210-Qfiling · viewer · series
22operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$23.5M2025-06-302026-08-0510-Qfiling · viewer · series

Limitations [top]

Peer group. Sector assignment from four-digit SIC codes, hand-tuned and published. The grade under three alternative peer policies is tabled above.

Size. Within a sector the letter tracks size. Among graded filers in the smallest asset band, 72% grade E and 0% grade A; in the largest, 13% grade E and 21% grade A. Universe as of Oct 9, 2026.

Failure model. filings 2012-01-01 to 2019-12-31 fit, filings 2020-01-01 to 2025-12-31 test; status post hoc pending confirmation. pre-registered on 2026 filings once their 12-month outcome windows close; supported if the paired per-quintile gain over the pooled model has a lower bound above 0.05.

Input validity. Revenue or total assets at or below $100,000 sets the degenerate-inputs flag. An input whose denominator is at or below $100,000 is left not computable rather than ranked.

Returns. No input on this page has a post-2015 confidence interval on returns that excludes zero. The grade ranks reported financial condition and is not a return forecast.